SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye's executive team will present the company and its programs in obesity and glaucoma at the following investment conferences:
Conference Details
BTIG Obesity Day
Date: May 8, 2024
Location: Virtual
Panel: 12:00-12:50 PM (ET), "CB1 Axis Therapies for Obesity"
Citizens JMP Life Sciences Conference
Date: May 13-14
Location: New York City
Presentation: Monday, May 13, 11:30 AM (ET)
1x1 meetings
Jefferies Global Healthcare Conference
Date: June 5th to 6th, 2024
Location: New York City
Presentation and 1x1 meetings
To register for these events, request a meeting or for more details, please contact your sales representative at the respective firms.
About Skye Bioscience
Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic ...